Introduction
============

*Verrucomicrobium spinosum* is a rod-shaped heterotrophic Gram-negative bacterium that is found in fresh water and soil environments and is characterized as being non-motile and contains appendages known as prosthecae. *V. spinosum* is important to the biotechnology and medical sectors as it is closely related to Chlamydia (Wagner and Horn, [@B29]). A recent study confirmed that the organism contains all the genetic components to encode a Type III Secretion System and was able to kill *Drosophila melanogaster* and *Caenorhabditis elegans*, two model invertebrate hosts (Sait et al., [@B23]).

Genomic analysis of *V. spinousm* show that the organism contains all the genes necessary for the synthesis of diaminopimelate/lysine *de novo* and thus the bacterium is prototrophic for lysine. Lysine is synthesized using two general pathways that are evolutionarily divergent with respect to the intermediates used. One pathway utilizes the intermediate α-amino adipic acid, which is derived from the metabolism of 2-ketoglutarate a product of the citric acid cycle. The α-amino adipic acid pathway is primarily used by fungi and is narrowly distributed to a few species belonging to the domain archaea (Nishida et al., [@B21]; Velasco et al., [@B28]). The other pathway employs the intermediate diaminopimelate, which is derived from oxaloacetate. The diaminopimelate pathway is found in most bacteria and photosynthetic organisms including cyanobacteria, algae, and plants.

Four variants of the diaminopimelate/lysine pathway have been discovered so far (Figure [1](#F1){ref-type="fig"}): the two acyl pathways, which use either succinyl or acetyl intermediates; the *meso*-diaminopimelate dehydrogenase pathway; and the recently discovered *L,L*-diaminopimelate aminotransferasae (DapL) pathway (Hudson et al., [@B14], [@B11]; McCoy et al., [@B19]). The biosynthesis of lysine from aspartate *via* the diaminopimelate/lysine pathway can be divided into three main events. The first event is the synthesis of tetrahydrodipicolinate from aspartate. This is a general feature of all four diaminopimelate pathway variants and is carried out by the enzymes, aspartate kinase, aspartate semialdehyde dehydrogenase, dihydrodipicolinate synthase, and dihydrodipicolinate reductase, respectively (Table [1](#T1){ref-type="table"}). The second event constitutes the conversion of tetrahydrodipicolinate to the penultimate intermediate *meso-*diaminopimelate. The synthetic steps from tetrahydrodipicolinate to *meso*-diaminopimelate define the uniqueness of the diaminopimelate variant pathways. In the acyl pathways, four enzymes are required. These reactions are carried out by the enzymes 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate *N*-acyl-transferase, acyl-diaminopimelate aminotransferase, acyl-diaminopimelate deacylase, and diaminopimelate epimerase, respectively (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). In the dehydrogenase pathway, tetrahydrodipicolinate is converted to *meso-*diaminopimelate by the enzyme *meso*-diaminopimelate dehydrogenase in one step circumventing the 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate-acyl-transferase, acyl-diaminopimelate aminotransferase, acyl-diaminopimelate deacylase, and diaminopimelate epimerase enzymatic reactions (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). The *L,L*-diaminopimelate aminotransferase (DapL) pathway synthesizes *L,L*-diaminopimelate from tetrahydrodipicolinate by a transamination reaction using glutamate as the amino donor and tetrahydrodipicolinate as the amino acceptor in a single reaction bypassing the 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate -acyl-transferase, acyl-diaminopimelate aminotransferase, acyl-diaminopimelate deacylase steps present in the succinylated or acetylated diaminopimelate/lysine pathways (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). The third and ultimate event in the diaminopimelate variant pathways is defined by the enzyme *meso*-diaminopimelate decarboxylase which catalyzes the decarboxylation of *meso-*diaminopimelate to synthesize lysine. This decarboxylation step is shared by all four variants (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}).

###### 

**List of diaminopimelate/lysine biosynthesis genes from *V. spinosum* DSM 4136^T^**.

  Locus tag            Gene symbol   Gene name                                                        EC \#       Reaction definition
  -------------------- ------------- ---------------------------------------------------------------- ----------- ------------------------------------------------------------------------------------------------------------------
  VspiD_010100025585   *lysC*        Aspartate kinase                                                 2.7.2.4     ATP+aspartate ↔ ADP+4-phospho-aspartate
  VspiD_010100030480   *asd*         Aspartate semialdehyde dehydrogenase                             1.2.1.11    aspartate 4-semialdehyde + orthophosphate + NADP^+^ ↔ 4-phospho-*L*-aspartate + NADPH + H^+^
  VspiD_010100011370   *dapA*        Dihydrodipicolinate synthase                                     4.2.1.52    Aspartate 4-semialdehyde + pyruvate ↔ *L*-2,3-dihydrodipicolinate + 2H~2~O
  VspiD_010100011365   *dapB*        Dihydrodipicolinate reductase                                    1.3.1.26    2,3,4,5-Tetrahydrodipicolinate + NADP + ↔ *L*-2,3-dihydrodipicolinate + NADPH + H^+^
  **-**                *dapD*        2,3,4,5-tetrahydropyridine-2,6-dicarboxylate Nacyl-transferase   2.3.1.117   Acyl-CoA + 2,3,4,5-tetrahydrodipicolinate + H~2~O ↔ CoA + *N*-acyl-2-*L*-amino-6-oxoheptanedioate
  **-**                *dapC*        Acyl-diaminopimelate aminotransferase                            2.6.1.17    *N*-acyl-*L,L*-2,6-diaminoheptanedioate + 2-oxoglutarate↔*N*-acyl-2-*L*-amino-6-oxoheptanedioate + *L*-glutamate
  **-**                *dapE*        Acyl-diaminopimelate deacylase                                   3.5.1.18    *N*-acyl-*L,L*-2,6-diaminoheptanedioate + H~2~O ↔ acyl + *L,L*-2,6-diaminoheptanedioate
  **-**                *ddh*         Diaminopimelate dehydrogenase                                    1.4.1.16    *meso*-2,6-Diaminoheptanedioate + NADP^+^ + H2O ↔ *L*-2-amino-6-oxoheptanedioate + NH~3~ + NADPH
  VspiD_010100012510   *dapL*        *L,L*-diaminopimelate aminotransferase                           2.6.1.83    *L,L*-2,6-diaminopimelate + 2-oxoglutarate ↔ 2,3,4,5-tetrahydrodipicolinate + *L*-glutamate + H~2~O
  VspiD_010100011375   *dapF*        Diaminopimelate epimerase                                        5.1.1.7     *L,L*-2,6-diaminopimelate↔*meso*-2,6-diaminopimelate
  VspiD_010100003650   *lysA*        Diaminopimelate decarboxylase                                    4.1.1.20    *meso*-2,6-Diaminopimelate→lysine + CO~2~

*The list was generated using the genomic information deposited in the IMG database (<http://img.jgi.doe.gov/cgi-bin/w/main.cgi>)*.

![**Diaminopimelate/lysine biosynthesis pathways**. The four variants of the diaminopimelate/lysine biosynthetic pathways starting from tetrahydrodipicolinate are denoted as **(A)** the succinylated or acetylated pathways, **(B)** the *meso*-diaminopimelate dehydrogenase pathway, and **(C)** the *L,L*-diaminopimelate aminotransferase (DapL) pathway. The abbreviations of the enzymes along with the enzyme reaction definitions are listed in Table [1](#T1){ref-type="table"}.](fmicb-03-00183-g001){#F1}

Since animals do not contain the machinery to synthesize diaminopimelate or lysine, which are used by bacteria for peptidoglycan biosynthesis, the enzymes involved in the bacterial diaminopimelate/lysine biosynthesis pathways are of interest to the scientific community. *meso*-Diaminopimelate serves as one of the cross linking amino acids in the cell wall of Gram-negative bacteria, whereas lysine has the same role in Gram-positive bacteria (Hutton et al., [@B15]). Inhibition of enzymes in the diaminopimelate/lysine biosynthesis pathways would have a detrimental effect to bacterial growth from two perspectives: since diaminopimelate is necessary for cell wall synthesis, cell lysis will occur as a result of osmotic pressure from the lack of peptidoglycan (Cox, [@B4]; Baizman et al., [@B2]); in addition, the inhibition of enzymes in the pathway will prevent protein synthesis, since lysine is one of the 20 common proteogenic amino acids. *meso*-Diaminopimelate is incorporated as one of the cross linking amino acids in the cell wall of Gram-negative bacteria by the enzyme UDP-*N*-acetylmuramoylalanyl-[d]{.smallcaps}-glutamyl-2,6-*meso*-diaminopimelate ligase (MurE) (E.C. 6.3.2.15), which is encoded by the *murE* gene.

The DapL pathway has been identified in numerous bacteria and been experimentally confirmed in a limited number of bacteria, some of which are deemed pathogenic (McCoy et al., [@B19]; Hudson et al., [@B11]; Liu et al., [@B17]). The three-dimensional crystal structure of DapL from *Arabidopsis thaliana* has been solved (Watanabe et al., [@B32], [@B30]) from *Chlamydia trachomatis* (Watanabe et al., [@B31]) and from the algae *Chlamydomonas reinhardtii* (Dobson et al., [@B5]; Hudson et al., [@B12]). Inhibitors for the Arabidopsis DapL ortholog have been reported using *in vitro* studies (Fan et al., [@B8]). It should be noted that although inhibitors the Arabidopsis DapL have been found, it is not known if these compounds inhibit other aminotransferases.

The identification of *dapL* and *murE* genes, in addition to the easy culturability and genetic manipulation of *V. spinosum*, makes the bacterium an excellent model organism for experiments addressing the essentiality of *dapL* and *murE* with respect to lysine and peptidoglycan biosynthesis (Domman et al., [@B6]). Most bacterial species that contain the DapL pathway are difficult to work with, since they are either slow growing, difficult to culture, anaerobic, and pathogenic to humans.

Here we present the first genomic and biochemical analysis of the diaminopimelate/lysine biosynthesis pathway from *V. spinosum*. We identify the genes necessary for diaminopimelate/lysine biosynthesis in the genome of *V. spinosum* and demonstrate that the bacterium uses the recently discovered DapL pathway for diaminopimelate/lysine biosynthesis. In addition, we identify and characterize MurE from *V. spinosum*, suggesting that the bacterium incorporates *m*eso-diaminopimelate into its peptidoglycan as a cross linking amino acid.

Results
=======

Identification of putative *dapL* and *murE* genes in *V. spinosum*
-------------------------------------------------------------------

The *dapL* ortholog from *V. spinosum* was identified using the DapL protein from *C. trachomatis Ct*390 *(*NP_219900) as the query with the BlastP algorithm from the Integrated Microbial Genomes (IMG) database[^1^](#fn1){ref-type="fn"}. This search identified a putative *L,L*-diaminopimelate aminotransferase annotated by the locus tag VspiD_010100012510 (ZP_02927470) that is 38% amino acid identity to the *C. trachomatis* DapL. The *murE* ortholog was identified using the *C. trachomatis* MurE (NP_219774) as a query. This search resulted in the identification of the *murE* ortholog from *V. spinosum* annotated by the locus tag VspiD_010100019130, which is 37% identical to the *C. trachomatis* MurE.

Crude soluble protein extract from *V. spinosum* contains DapL activity
-----------------------------------------------------------------------

If *V. spinosum* utilizes the DapL pathway for diaminopimelate/lysine biosynthesis, as suspected by the genomic analysis, a crude soluble protein extract should possess DapL activity. The *ortho*-aminobenzaldehyde assay was employed using a crude soluble protein extract from *V. spinosum*. Using *L,L*-diaminopimelate as the amino donor and 2-ketoglutarate as the amino acceptor, the assay measures the production of dihydroquinazolium which is the product of the interaction between tetrahydrodipicolinate and *ortho*-aminobenzaldehyde. DapL activity was detected from the crude soluble extract showing that the rate of the reaction is proportional to the amount of *V. spinosum* protein extract added to the assay (Figure [2](#F2){ref-type="fig"}). Enzymatic activity was not observed when the amino donor, or amino acceptor, was omitted from the assay. In addition, no activity was observed when the protein extract was heated in boiling water for 5 min.

![**DapL activity from crude protein extract from *V. spinosum***. The graph shows the relationship between the protein amount and reaction rate. The DapL *ortho*-aminobenzaldehyde assay is described in the Section ["Methods."](#s1){ref-type="sec"} The assay was done in triplicates for each protein concentration.](fmicb-03-00183-g002){#F2}

DapL is the only route for diaminopimelate/lysine biosynthesis in *V. spinosum*
-------------------------------------------------------------------------------

The genome of *V. spinosum* was searched to catalog the genes necessary for the *de novo* anabolism of lysine from aspartate. Since DapL activity was detected from a soluble extract, we wanted to know whether the DapL pathway was the sole route toward lysine biosynthesis. There are examples in the literature of multiple pathways for lysine biosynthesis in bacteria; for example, the genomes of *Bacteroides fragilis* and *Clostridium thermocellum* were found to contain both the DapL and *meso*-diaminopimelate dehydrogenase pathways (Hudson et al., [@B13]). Also, *Corynebacterium glutamicum* employs the acyl pathway in conjunction with the Ddh pathway (Schrumpf et al., [@B26]). A search of the *V. spinosum* genome suggests that the DapL pathway is the only route for diaminopimelate/lysine biosynthesis, since orthologs of the acyl and dehydrogenase genes could not be identified in the genome (Table [1](#T1){ref-type="table"}; Figure [1](#F1){ref-type="fig"}). Even though the search did not identify a diaminopimelate dehydrogenase ortholog, we tested for dehydrogenase activity using the same protein extract that was used to detect DapL activity. This test was done using 1.0 mg of total protein in two different buffer systems, finding no activity. The recombinant diaminopimelate dehydrogenase from *Clostridium thermocellum* was used as a positive control (Hudson et al., [@B13]). This result was consistent with the genomic analysis regarding the absence of a diaminopimelate dehydrogenase ortholog in the genome of *V. spinosum*.

The gene annotated by the locus tag VspiD_010100012510 (*Vsdap*L) encodes an authentic *L,L*-diaminopimelate aminotransferase
-----------------------------------------------------------------------------------------------------------------------------

The putative *VsdapL* gene was cloned and the recombinant enzyme was purified to homogeneity using affinity chromatography (Figure [3](#F3){ref-type="fig"}). The *ortho*-aminobenzaldehyde assay was used to determine whether the putative *Vs*DapL had *L,L*-diaminopimelate aminotransferase activity. The results from this analysis show that the open reading frame annotated by the locus tag encodes an authentic *L,L*-diaminopimelate aminotransferase enzyme. With *L,L*-diaminopimelate as the amino donor and 2-ketoglutarate as the amino acceptor, the specific activity of the *Vs*DapL is 4.1 ± 0.25 Δ*A*~440~ min^−1^ mg^−1^. Unlike the plant and algae enzyme, *Vs*DapL possesses transamination activity with several diamine donors that are structurally similar to *L,L*-diaminopimelate, including the racemic isomer *meso*-diaminopimelate (Table [2](#T2){ref-type="table"}), albeit at relatively low rates. The enzyme is also able to use several oxoacids as amino acceptors in addition to 2-ketoglutarate (Table [2](#T2){ref-type="table"}); again the relative rates are low.

###### 

**Activity of *Vs*DapL with various amino donors and amino acceptors**.

  Amino donor              Relative activity (%)   Amino acceptor    Relative activity (%)
  ------------------------ ----------------------- ----------------- -----------------------
  *L,L*-diaminopimelate    100                     2-Ketoglutarate   100
  *meso*-Diaminopimelate   1.6 ± 0.35              Pyruvate          8.1 ± 0.3
  *L*-Lysine               3.0 ± 0.2               Oxaloacetate      7.4 ± 0.15
  *L*-Ornithine            5.1 ± 0.2               Oxovalerate       7.9 ± 0.15

*The assay measures the production of dihydroquinazolium at 440 nm using the *ortho*-aminobenzaldehyde assay. The assays pertaining to each amino donor/acceptor combination was done in triplicates, the relative activity is based on the activity of the enzyme with *L,L*-diaminopimelate and 2-ketoglutarate as substrates*.

![**Recombinant expression and purification of *Vs*DapL using affinity chromatography**. Lane (1) Protein Marker (kDa), Lane (2) 10 μg of soluble protein from uninduced cells, Lane (3) 10 μg of soluble proteins from induced cells, Lane (4) 1 μg of purified *Vs*DapL. The proteins were resolved on a 10% (w/v) acrylamide gel and were stained with Coomassie blue for visualization.](fmicb-03-00183-g003){#F3}

*VsdapL* is able to functionally complement the *E. coli* *ΔdapD/dap*E (AOH1) mutant
------------------------------------------------------------------------------------

The *E. coli* strain AOH1 harbors a deletion of the *dapD* gene and a mutation in *dapE* that renders this enzyme non-functional (Hudson et al., [@B14]). As such, the mutant is unable to synthesize *meso*-diaminopimelate for lysine and cell wall biosynthesis. As a result, the cells lyse from osmotic pressure due to the lack of *meso*-diaminopimelate as a cross linking amino acid in the cell wall and is deemed auxotrophic for diaminopimelate and lysine. For complementation analysis, *E. coli* AOH1 was transformed with the empty vector (pBAD33), or with the DapL expression vectors (pBAD33 + *dapL*) from the plant *Arabidopsis thaliana* (*AtdapL*; Hudson et al., [@B14]), the alga *C. reinhardtii* (*CrdapL*; Dobson et al., [@B5]) or the bacterium *V. spinosum* (*VsdapL*). While *E. coli* AOH1 is able to grow on media supplemented with *L,L*-diaminopimelate, only the auxotrophic mutant expressing authentic orthologous DapLs are able to grow on *L,L*-diaminopimelate-free media (Figure [4](#F4){ref-type="fig"}). This analysis demonstrates that the recombinant enzymes are able to convert tetrahydrodipicolinate to *L,L*-diaminopimelate, bypassing three acyl enzymatic reactions present in the *E. coli* acyl pathway, to facilitate the synthesis of *meso*-diaminopimelate for lysine and cell wall biosynthesis (Figures [1](#F1){ref-type="fig"} and [5](#F5){ref-type="fig"}).

![**Functional complementation of *E. coli* Δ*dapD/dapE* (AOH1) mutant**. The AOH1 mutant harboring the plasmids pBAD33, pBAD33 + *AtdapL*, pBAD33 + *CrdapL*, and pBAD33 + *VsdapL* was replica-plated on LB medium supplemented with 0.2% (w/v) arabinose with or without 50 μg/mL *L,L*-diaminopimelate. For presentation purposes only one colony from the vector only and recombinant plasmids are represented in the diagram.](fmicb-03-00183-g004){#F4}

![**Schematic representation of the bacterial peptidoglycan synthesis using *m*-DAP as one of the cross linking amino acids**. The cytosolic, membrane, and periplasmic steps are shown. The abbreviations of the enzymes are as follows: MurA (UDP-*N*-acetylglucosamine enolpyruvyl transferase), MurB (UDP-*N*-acetylenolpyruvoylglucosaminereductase), MurC (UDP-*N*-acetylmuramate-*L*-alanine ligase), MurD (UDP-*N*-acetyl-muramoylalanine-[d]{.smallcaps}-glutamate ligase), MurE (UDP-*N*-acetylmuramoyl-*L*-alanyl-[d]{.smallcaps}-glutamate 2,6-*meso*-diaminopimelate ligase), MurF (UDP-*N*-acetylmuramoyl-tripeptide-[d]{.smallcaps}-alanyl-[d]{.smallcaps}-alanine ligase), Ddl ([d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine ligase B), MraY (phospho-*N*-acetylmuramoyl-pentapeptide-transferase), MurG (pyrophosphoryl-undecaprenol-*N*-acetylglucosamine transferase), and PBPs (penicillin binding proteins).](fmicb-03-00183-g005){#F5}

*Vs*DapL belongs to the DapL1 form of *L,L*-diaminopimelate aminotransferases
-----------------------------------------------------------------------------

Diaminopimelate aminotransferases are approximately 400 amino acids in length and are members of the pyridoxal-5′phosphate dependent family of class I/II transaminases. A recent study revealed that there are two diverged forms of DapL enzymes; DapL1 and DapL2 (Hudson et al., [@B11]). The two forms of DapLs share approximately 30% homology on the amino acid level. The DapL ortholog from *C. trachomatis* is evolutionarily related to DapL1 enzymes (Hudson et al., [@B11]). Since the homology of the *V. spinosum* DapL is only 38% to the *C. trachomatis* ortholog, the form of the *V. spinosum* DapL was not apparent. Using phylogenetic analysis, the DapL ortholog from *V. spinosum* clusters with enzymes some of which have been experimentally confirmed as DapL1 orthologs and from pathogenic organisms (Hudson et al., [@B11], [@B13]). The analysis shows two distinct clades, DapL1, DapL2. The aspartate aminotransferase from *Yersinia pseudotuberculosis*, which is also classified as a class I/II transaminase is used as an outgroup (Figure [6](#F6){ref-type="fig"}). Four analyses were performed (ML, MP, ME, NJ) and all show moderate to strong support the DapL2 clade (57--100%) and for the DapL1 clade (56--99%). The more variable maximum likelihood bootstrap support is alignment dependent with alternative alignments techniques (Clustal vs. MUSCLE) exhibiting higher ML bootstrap values for the DapL1 and DapL2 clades respectively. Muscle-aligned sequences generally exhibit higher bootstrap support for both DapL1 and DapL2 clades than Clustal.

![**Phylogenetic relationship of DapL amino acid sequences**. The *Vs*DapL ortholog is annotated with a black circle. Minimum evolution (ME) topology shown with maximum likelihood (ML), maximum parsimony (MP), minimum evolution (ME), and neighbor-joining (NJ) bootstrap values for both the DapL1 and DapL2 clades (from left to right). Branch lengths are proportional to divergence; the scale below the tree indicates percent divergence of the branch lengths. The tree was rooted with a single outgroup aspartate aminotransferase (AspC) from *Y. pseudotuberculosis*. Figure drawing produced using FigTree (ver. 1.6.1; Rambaut, [@B22]).](fmicb-03-00183-g006){#F6}

*VsmurE* is able to functionally complement the *E. coli murE* mutant
---------------------------------------------------------------------

*meso*-Diaminopimelate serves not only as the penultimate precursor for lysine biosynthesis, but it is also incorporated as one of the cross linking amino acids in the cell wall of Gram-negative bacteria. This is facilitated by the enzyme UDP-*N*-acetylmuramoylalanyl-*D*-glutamyl-2,6-*meso*-diaminopimelate ligase (MurE; Figure [5](#F5){ref-type="fig"}). Since *V. spinosum* is classified as Gram-negative bacterium, it should possess a MurE ortholog (Schlesner et al., [@B25]). The *VsmurE* ortholog was identified and the open reading frame was cloned into an expression vector to test *via* functional complementation whether the gene encodes an authentic MurE enzyme. The *E. coli* mutant TKL-11 harbors a mutation in the *murE* gene which results in a temperature sensitive growth phenotype where the mutant is able to grow at the permissive temperature of 30°C, but not at 42°C (Lugtenberg and van Schijndel-van Dam, [@B18]). The mutant was transformed with an empty vector (pBAD33) and a vector expressing the putative MurE (pBAD33 + *VsmurE*). Using replica-plating, the results from this analysis demonstrate that at the permissive temperature of 30°C, the mutant harboring both the vector control and the vector expressing the recombinant enzyme are able to grow. However, when exposed to the non-permissive temperature of 42°C, only the mutant expressing the MurE ortholog is able to grow (Figure [7](#F7){ref-type="fig"}A). This result was corroborated by assessing bacterial growth over a period of 10 h. At 30°C the mutant harboring the vector only and the *murE* expression vector grew as expected. However, when the cultures were switched to the non-permissive temperature of 42°C after 5 h from 30°C, only the mutant harboring the *murE* expression vector continued to grow. The optical density of the vector only culture declined which can be attributed to rapid lysis of the cell due to the lack of proper peptidoglycan synthesis (Figure [7](#F7){ref-type="fig"}B). The assessment of crude soluble protein extracts from the complementation experiment using SDS-PAGE analysis confirmed the expression of the recombinant MurE (59 kDa) in TKL-11 cells harboring the expression vector (pBAD33 + *VsmurE*) grown at 42°C that is not present in the extract from TKL-11 harboring the vector only control (pBAD33) grown at 30°C (Figure [7](#F7){ref-type="fig"}C).

![**Functional complementation of the *E.coli murE* mutant**. **(A)** The *E. coli* mutant TKL-11 harboring pBAD33 or pBAD33 + *VsmurE*. The bacteria were grown to an OD of 0.1 at 600 nm and were serially diluted to 10^−1^, 10^−2^, and 10^−3^ using 0.85% (w/v) saline. The bacteria were replica-plated on LB medium supplemented with 0.2% (w/v) arabinose. The growth was assessed at 30 and 42°C after 24 h. Only one colony from the vector only and recombinant plasmid was used to create the diagram. **(B)** Growth curve of *E. coli* TKL-11 harboring either the empty vector pBAD33 (circles), or pBAD33 + *VsmurE* (triangles). The cells were grown at 30°C for 5 h then shifted to 42°C for an additional five hours (shaded area). **(C)** SDS-PAGE analysis of proteins extracted from TKL-11 grown in LB supplemented with 0.2% arabinose (w/v). Lane (1) protein ladder (kDa), Lane (2) 10 μg of soluble protein extract from TKL-11 harboring pBAD33 grown at 30°C, Lane (3) 10 μg of soluble protein extract harboring pBAD33 + *VsmurE* grown at 42°C. The proteins were resolved on a 10% (w/v) acrylamide gel and were stained with Coomassie blue for visualization.](fmicb-03-00183-g007){#F7}

The amino acids that constitute the active site are conserved in *Vs*DapL
-------------------------------------------------------------------------

To examine more closely the *Vs*DapL variant at the amino acid level, we aligned its amino acid sequence to that of three DapL orthologs already functionally and structurally characterized from *Arabidopsis thaliana* (Watanabe et al., [@B32]), *C. reinhardtii* (Dobson et al., [@B5]), and *C. trachomatis* (Watanabe et al., [@B31]; Figure [8](#F8){ref-type="fig"}). The *Vs*DapL sequence has more similarity to the *Cr*DapL and *At*DapL sequences, but like the *Ct*DapL sequence, has a truncated N-terminal region. The longer N-terminal regions for the eukaryotic sequences is attributed to subcellular localization sequences, used by *A. thaliana* and *C. reinhardtii* to target the enzyme to the chloroplast, where lysine biosynthesis in known to occur (Mills and Wilson, [@B20]). As can be seen in Figure [8](#F8){ref-type="fig"} (residues in red bold), the putative active site residues are well conserved between the four DapL enzymes. In addition, the loop regions that form the active site cleft are generally well conserved. In particular, loops A and C are well conserved, although loop B shows more variability. From previous structural studies (Watanabe et al., [@B32], [@B31]; Dobson et al., [@B5]), it is known that loop B is disordered and its role in catalysis is less clear. However, noting the increased substrate promiscuity displayed by *Vs*DapL, it is possible that loop B may be involved in the substrate binding step.

![**Protein sequence alignment of DapL from *V. spinosum, C. trachomatis, A. thaliana*, and *C. reinhardtii* generated using the ClustalW server (<http://www.ebi.ac.uk/Tools/msa/clustalw2/>)**. Putative active-site residues, based on the structural studies of the ligand bound *At*DapL and *Cr*DapL enzymes, are shown in red. The loop regions correspond to the key loops that line the active site, where the asterisk refers to the loop contributing to the active site of the opposing monomer. The ClustalW scores relative to the *V. spinosum* sequence were: *vs. C. reinhardtii* = 49 (length = 443 residues, identity); *vs. A. thaliana* = 45 (length = 426 residues); *vs. C. trachomatis* = 39 (length = 394 residues).](fmicb-03-00183-g008){#F8}

A homology model of the *Vs*DapL was generated using the Swiss-Model Protein Modeling Server (Figure [9](#F9){ref-type="fig"}). The tertiary structure of the DapL monomer has been annotated as having a large and a small domain, which also includes the arm region (Figure [9](#F9){ref-type="fig"}A). Most aminotransferases are approximately 100 kDa in mass, representing a homodimeric quaternary structure. Assuming that the functional unit of the *Vs*DapL enzyme is a dimer, which is required for proper orientation of the conserved active site residues within the active site, *Vs*DapL probably has two active sites (Figure [9](#F9){ref-type="fig"}B). Closer examination of one active site (Figure [9](#F9){ref-type="fig"}C) highlights those residues that are conserved from the multiple sequence alignment (Figure [8](#F8){ref-type="fig"}) and the key loop regions that line the active site. Importantly, the model predicts that loop B is positioned at the entrance of the active site cleft, ideally placed to interact with substrates entering the active site.

![***Vs*DapL homology model generated with the Swiss-Model Protein Modeling Server (Arnold et al., [@B1]) using the *Cr*DapL apo structure as a template (PDB id: 3QGU Dobson et al., [@B5]; Hudson et al., [@B12], BLAST identity = 51% (207/404 residues), QMEAN4 score = 0.673)**. **(A)** The domain structure of the monomer. Note that, as seen in Figure [8](#F8){ref-type="fig"}, *Vs*DapL has a truncated N-terminal arm region compared to *Cr*DapL and *At*DapL. **(B)** Assuming a dimeric structure, which is required to place the conserved active site resides (highlighted in red bold Figure [8](#F8){ref-type="fig"}), the two active sites of the dimer are shown. **(C)** A close up view of active site 1 showing the conserved active site residues and the loops lining the active site (as per Figure [8](#F8){ref-type="fig"}).](fmicb-03-00183-g009){#F9}

Discussion
==========

The discovery of a new biosynthetic route to diaminopimelate and lysine in plants, algae, and bacteria provides a fresh target for the discovery of novel herbicides, algaecides, and antibiotics. The amino acids that constitute the active site of DapL are conserved in the *V. spinosum* ortholog based on protein alignment and modeling. Therefore, inhibitors of *Ct*DapL and *At*DapL are likely to inhibit *Vs*DapL. To this end, *V. spinosum* is a suitable bacterial system for the development of *in vivo* assays for the discovery of compounds that are able to inhibit DapL to facilitate antibiotic development.

Since *V. spinosum* can be genetically altered using exogenous DNA, *V. spinosum* is an excellent candidate for determining the essentiality of *dapL via* mutagenic experiments using transposon and or homologous recombination. Moreover, the organism is aerobic, relatively easy to culture and non-pathogenic to humans, unlike other bacteria that contain the DapL pathway, such as *Leptospira interrogans*, *Bacteriodes fragilis*, and *C. trachomatis* (McCoy et al., [@B19]; Hudson et al., [@B11]).

Recently, our laboratories demonstrated that the orthologous *dapL* from the model plant system *Arabidopsis thaliana* is essential for growth and development (Dobson et al., [@B5]). However, it is not known if the same is true for bacteria that exclusively utilize the DapL pathway for diaminopimelate/lysine synthesis. It is not known whether another aminotransferase capable of interconverting tetrahydrodipicolinate and *L,L*-diaminopimelate exists in bacteria that solely contain the DapL pathway. Thus, a suitable *dapL* bacterial mutant that is auxotrophic for diaminopimelate/lysine would be an important step forward especially since there are examples in the literature regarding substrate promiscuity of aminotransferases involved in amino acid metabolism. For instance, the aspartate aminotransferase, tyrosine aminotransferase, and the branched-chain amino acid aminotransferase have been shown to possess overlapping activities in *E. coli* (Gu et al., [@B9]). In addition, a recent study demonstrated that three aminotransferases are involved in alanine biosynthesis in *E. coli* (Yoneyama et al., [@B34]).

Aminotransferases are common in the genome of *V. spinosum* given their integral role in multiple anabolic and catabolic pathways. If a compound inhibits a bacterial DapL *in vitro*, as in the case of the Arabidopsis enzyme, the question of whether this compound is specific for DapL *in vivo* will have to be investigated. One way to answer this question would be to use *in vivo* studies by exposing the putative inhibitory compound to a *dapL* mutant supplemented with diaminopimelate in the medium to observe the growth phenotype. If the inhibitory compound is specific for DapL, one would expect that it will not have any effect on the mutant. However, the same compound should have an effect on the wild-type parental strain used to create the *dapL* mutant. The inhibition of DapL will prevent *m*-DAP production which would lead to cell death caused by the lack of proper protein and cell wall biosynthesis.

Here we present the elucidation of the biosynthetic pathway of diaminopimelate/lysine from *V. spinosum* using genomic, biochemical, and structural approaches. The enzymes involved in the bacterial diaminopimelate/lysine biosynthetic pathways are presumed targets for antibiotic development. The identification and characterization of these enzymes provides valuable information pertaining to experiments aiming to elucidate the essentiality of genes involved in the bacterial diaminopimelate/lysine biosynthesis pathways. The DapL pathway is the sole route toward diaminopimelate/lysine in *V. spinosum*. In addition, the bacterium can be genetically modified, the organism is relatively easy to culture and non-pathogenic to animals. These criteria make *V. spinosum* an excellent bacterial model for elucidating the essentiality of genes involved in diaminopimelate/lysine metabolism.

Materials and Methods {#s1}
=====================

*V. spinosum* growth conditions
-------------------------------

The plasmids and strains used in this study are listed in Table [3](#T3){ref-type="table"}. The *V. spinosum* DSM 4136^T^ organism was cultured in R2A medium at 26°C.

###### 

**Plasmids and strains used in this study**.

  Plasmid/strains                        Vendor/Reference
  -------------------------------------- -----------------------------------------------
  pET30A                                 Novagen, USA
  pET100D/Topo                           Invitrogen, USA
  pBAD33                                 Guzman et al. ([@B10])
  pBAD33 + *AtdapL*                      Hudson et al. ([@B14])
  pBAD33 + *CrdapL*                      Dobson et al. ([@B5])
  pET30A + *VsdapL*                      This study
  pET100D + *VsmurE*                     This study
  pBAD33 + *VsdapL*                      This study
  pBAD33 + *VsmurE*                      This study
  *Verrucomicrobium spinosum* DSM 4136   Schlesner ([@B24])
  5-alpha competent cells                New England Biolabs, USA
  BL21 codon plus RIPL                   Agilent Technologies, USA
  AOH1 (Δ*dapD/dapE*)                    Hudson et al. ([@B14])
  TKL-11 (*murE*)                        Lugtenberg and van Schijndel-van Dam ([@B18])

Multiple-protein sequence alignment, phylogenetic tree construction, and homology model of *Vs*DapL
---------------------------------------------------------------------------------------------------

A DapL protein sequence alignment was generated using the ClustalW server[^2^](#fn2){ref-type="fn"}. Phylogenetic trees were constructed from MUSCLE aligned amino acid sequences using maximum likelihood (ML), maximum parsimony (MP) minimum evolution (ME), and neighbor-joining (NJ) techniques in MEGA 5.05 (Tamura et al., [@B27]). ML searches were performed using the likelihood-based WAG (Whelan and Goldman, [@B33]) model of amino acid character evolution, gamma distributed rates across sites, and the proportion of invariant sites estimated from the data set (WAG + G + I). ME and NJ tree searches were performed using the parsimony-based JTT model (Jones et al., [@B16]) and gamma distributed rates (JTT + G). Optimal models were determined by MEGA 5.05 that iteratively tests the partition against hierarchically nested models of evolution to obtain the best fit. Node strength was assessed using the bootstrap technique and 100 pseudo-replicate data sets for each analysis type (ML, MP, ME, and NJ). The accessions numbers for the following DapL proteins are: *Arabidopsis thaliana* (AEE86265), *V. spinosum* (ZP_02927470), *C. reinhardtii* (XP_001693061), *C. trachomatis* (NP_219900), *Parachlamydia* UWE25 (YP_007684), *Synechocystis* sp. PCC 6803 (BAA10583), *Thermosynechococcus elongatus* BP1 NP_682892), *Bacteroides fragilis* NCTC 9343 (YP_212286), *Clostridium thermocellum* 27405 (YP_001039489), *Methanothermobacter thermoautotrophicus* (NP_275195), *Geobacter sulfurreducens* (NP_951224), *Leptospira interrogans* (YP_002757), *Nostoc* PCC 7120 (NP_488367), *Gloeobacter violaceus* PCC 7421 (NP_927054), *Methanosaeta thermophila* PT (YP_843230), *Methanospirillum hungatei* JF1 (YP_504354), *Dehalococcoides* CBDB1 (YP_307791), *Methanococcoides burtonii DSM* 6242 (YP_565702), *Methanosarcina barkeri Fusaro* (YP_306095), *Methanosarcina acetivorans* C2A (NP_616639), *Syntrophobacter fumaroxidans* MPOB (YP_844192), *Planctomyces brasiliensis* DSM 5305 (YP_004269630), *Planctomyces limnophilus* DSM 3776 (YP_003632005), *Verrucomicrobiae bacterium* DG1235 (ZP_05058547). The accession number for the *Yersinia pseudotuberculosis* IP 32953 aspartate aminotransferase (AspC) is (CAH20674).

A homology model of the *Vs*DapL protein was generated using the Swiss-Model Protein Modeling Server (Arnold et al., [@B1]) using the *Cr*DapL apo structure as a template (PDB id: 3QGU; Dobson et al., [@B5]). The model was examined by hand for clashes and appropriate geometry using the visualization software COOT (Emsley and Cowtan, [@B7]).

PCR amplification and cloning of the *V. spinosum dapL* and *murE* open reading frames
--------------------------------------------------------------------------------------

The full length ORFs annotated by the locus tags VspiD_010100012510 (*dapL*, *L,L*-diaminopimelate aminotransferase) and VspiD_010100019130 (*murE*, UDP-*N*-acetylmuramoylalanyl-[d]{.smallcaps}-glutamyl-2,6-*meso*-diaminopimelate ligase) were amplified by PCR. The ORFs were amplified using: 12 pmol of forward and reverse primers, 1 mM MgSO~4~, 0.5 mM of each of the four deoxynucleotide triphosphates, 0.5 ng of genomic DNA and 1 unit of Platinum *Pfx* DNA polymerase (Invitrogen Corporation, Carlsbad, CA, USA) using the following PCR conditions: 1 cycle at 94°C for 2 min, followed by 30 cycles of 94°C for 15 s, 60°C for 30 s and 72°C for 2 min. The forward and reverse primers used to amplify the ORFs were *VsdapL* F and *VsdapL* R for the *dapL* ORF and *VsmurE* F and *VsmurE* R for the *murE* ORF. The nucleotide sequences of the primers are listed in Table [4](#T4){ref-type="table"}. The underlined sequence represents the restriction enzyme sites used to facilitate cloning of the ORF while the bolded and italicized sequences represent initiation and termination codons. For cloning, the *dapL* PCR fragment was digested with *Eco*RI and *Sal*I and ligated into the plasmid pET30a (EMD Biosciences, Gibbstown, NJ, USA) to produce the plasmid pET30a + *VsdapL*. The *murE* PCR fragment was ligated into the plasmid pET100D/topo (Invitrogen Corporation, Carlsbad, CA, USA) to produce the plasmid pE100D + *VsmurE*. The recombinant protein derived from this plasmid carries a hexa-histidine tag derived from pET30a and pET100D plasmids at the amino terminus. To confirm the fidelity of the PCR reactions, the *dapL* ORF was sequenced from pET30a using the T7 promoter and the T7 terminator primer (Table [4](#T4){ref-type="table"}). The *murE* ORF was sequenced from pET100D using the T7 promoter and T7 R primer (Table [4](#T4){ref-type="table"}). Both the *dapL* and *murE* ORFs are 100% identical to the sequences deposited in the Integrated Microbial Genomes (IMG) public database[^3^](#fn3){ref-type="fn"}.

###### 

**List of Primers used for PCR amplification, cloning and nucleotide sequencing**.

  Primer name     Sequence (from 5′ to 3′)
  --------------- -----------------------------------------------------
  *VsdapL* F      CCCC[GAATTC]{.ul}**ATG**GCCCTCATCAACGAAAACTTCCTCAAG
  *VsdapL* R      CCCC[GTCGAC]{.ul}**CTA**CTTCAGCGCGGCGATACGGCGGCAGAC
  *VsmurE* F      CACC**ATG**ACCATTTTGCGCGATCTTATCGAGGGT
  *VsmurE* R      [GTCGAC]{.ul}**TCA**CTGACGGTCATCCCTCCTTTGGCGTGC
  T7 promoter     TAATACGACTCACTATAGGG
  T7 R            TAGTTATTGCTCAGCGGTGG
  T7 terminator   TATGCTAGTTATTGCTCAG

*The underlined sequences represent restriction enzyme sites. The bolded and italicized sequences are denoted as the start and stop codons for the open reading frames (ORFs)*.

Functional complementation plasmid constructs
---------------------------------------------

The plasmids used for functional complementation of the *E. coli* Δ*dapD/dapE* double mutant and the *E. coli murE* mutant were produced by sub-cloning the *Xba*I and *Sal*I fragment from pET30a + *VsdapL* and the pET100D + *VsmurE* plasmids into pBAD33 to produce pBAD33 + *VsdapL* and pBAD33 + *VsmurE* (Guzman et al., [@B10]). The fusion proteins produced from the pBAD33 constructs are identical to the proteins produced from the pET30a and pET100D constructs.

Functional complementation of the *E. coli dapD/E* and *murE* mutants
---------------------------------------------------------------------

The *E. coli* mutant AOH1 (Δ*dapD::Kan2, dapE6*) was transformed with pBAD33 or plasmids harboring *dapL* orthologs from *V. spinosum* (pBAD33 + *VsdapL*), *Arabidopsis thaliana* (pBAD33 + *AtdapL*), and *C. reinhardtii* (pBAD33 + *CrdapL*). Transformants were selected on LB agar medium supplemented with 50 μg mL^−1^ DAP and 34 μg mL^−1^ chloramphenicol. Ten individual colonies from the vector only and the recombinant plasmid were then replica-plated onto LB medium plus 0.2% (w/v) arabinose with or without 50 μg mL^−1^ DAP. The cultures were grown at 30°C for 24 h. The *E. coli murE* mutant (TKL-11) (*thr-1*, *leuB6* (Am), *murE1*, *fhuA21*, *codA1*, *lacY1*, *tsx-95*, *glnV44* (AS), λ^−^, *pyrF101*, *his-108*, *thyA6*, *argG66*, *ilvA634*, *thi-1*, *deoC1*) was transformed with pBAD33 or pBAD33 + *VsmurE* (Table [3](#T3){ref-type="table"}). Transformants were selected on LB agar medium supplemented with 50 μg mL^−1^ thymine and 34 μg mL^−1^ chloramphenicol at 30°C. Ten individual colonies from the vector only and recombinant plasmid transformation were replica-plated onto LB medium plus 0.2% (w/v) arabinose and 50 μg mL^−1^ thymine. The cultures were grown at 30 and 42°C for 24 h to assess functional complementation.

Protein expression and purification of *Vs*DapL
-----------------------------------------------

The *E. coli* BL21-CodonPlus-RIPL strain was transformed with the plasmid pET30a + *VsdapL* and grown in LB broth containing 50 μg mL^−1^ kanamycin and 34 μg mL^−1^ chloramphenicol at 37°C to an OD~600~ of 0.5. Protein expression was induced in 1.0 L of culture using isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside to a final concentration of 0.5 mM for 6 h at 20°C. The cell pellet was lysed by sonication in a solution of 50 mM sodium phosphate (pH 8.0) and 300 mM NaCl. The soluble extract was incubated with 1 mL bed volume of Talon Metal Affinity Resin (Clontech, Mountain View, CA, USA) for 30 min at 4°C. The resin was washed five times with 30 mL of sonication buffer containing 10 mM imidazole (pH 8.0) for 15 min each. The enzyme was eluted with 10 mL of sonication buffer containing 250 mM imidazole (pH 8.0). The pure protein was concentrated in an Amicon Ultra 10,000 molecular weight cutoff filter unit replacing the elution buffer with 100 mM HEPES-KOH containing 1 mM DTT, 2 mM EDTA (pH 7.6). The recombinant protein was stored in 50% glycerol. Protein concentration was measured using the Bradford assay with bovine serum albumin as the standard (Bradford, [@B3]).

*L,L*-diaminopimelate aminotransferase enzyme *ortho*-aminobenzaldehyde assay
-----------------------------------------------------------------------------

The *ortho*-aminobenzaldehyde assay measured the formation of THDPA from *L,L*-DAP using *ortho*-aminobenzaldehyde, which forms a dihydroquinazolium adduct with a maximum absorbance at 440 nm. The assay contained 100 mM HEPES-KOH (pH 7.6), 0.5 mM amino donor, 2 mM amino acceptor and 1.25 mM *ortho*-aminobenzaldehyde and 10.0 μg of purified recombinant *Vs*DapL enzyme in a 0.5 mL reaction. The reactions were incubated at 30°C and the change in absorbance was measured continuously at 440 nm using a Beckman DU640 spectrophotometer.

*meso*-diaminopimelate dehydrogenase activity
---------------------------------------------

Ddh activity was assessed using oxidative deamination. The assay consisted of 0.5 mM *m-*DAP, 0.5 mM NADP^+^, and 1 mg of crude soluble *V. spinosum* extract or 10 μg of pure recombinant *meso*-diaminopimelate dehydrogenase from *C. thermocellum* (Hudson et al., [@B13]) in 100 mM glycine-KOH (pH 10.5) or 100 mM HEPES-KOH (pH 7.6) in a final volume of 0.5 mL. The production of NADPH was measured continuously at 340 nm at 30°C using a Beckman DU640 spectrophotometer
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